SOURCE: Equity News Circuit

Equity News Circuit

May 16, 2013 08:45 ET

Free Research Reports on APRI, DVR, MRIN and OPTR Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwired - May 16, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Apricus Biosciences Inc. (NASDAQ: APRI) shares surged 19.05 percent on volume of over 1.0 million shares traded to close at $3.00 a share. Vitaros, Apricus Bio's lead product candidate for the treatment of ED, has been approved for sale in Canada, but won't be launched in the first half of 2013.

Find out more about Apricus Biosciences including full access to the free equity report at: www.BedfordReport.com/APRI

Cal Dive International, Inc. (NYSE: DVR) shares soared 19.39 percent on volume of nearly 13.0 million shares traded Wednesday to close at $1.97 a share. The company announced that it has been awarded two additional contracts from Pemex Exploración y Producción totaling approximately $188 million.

Find out more about Cal Dive International including full access to the free equity report at: www.BedfordReport.com/DVR

Marin Software Inc. (NYSE: MRIN) shares rallied 13.34 percent on volume of 2.27 million shares traded to close at $10.62 a share. The company reported net revenues totaled $17.2 million for the first quarter of 2013, an increase of 32 percent when compared to revenues of $13.0 million in the year ago quarter.

Find out more about Marin Software including full access to the free equity report at: www.BedfordReport.com/MRIN

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) shares spiked 13.54 percent on volume of over 5.0 million shares traded to close at $16.18 a share. The company reported total revenues of $19.4 million for the first quarter of 2013, compared to $14.4 million in the year ago quarter. Optimer has recently appointed Mr. Eric Sirota as Chief Operating Officer.

Find out more about Optimer Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/OPTR

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information